snippet
Noveome Biotherapeutics has launched a new programme to assess its ST26 product candidate for the treatment of the severe inflammatory cytokine storm response associated with COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
Source
Pharmaceutical Business Review